<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037543</url>
  </required_header>
  <id_info>
    <org_study_id>08-HM10460A-101</org_study_id>
    <nct_id>NCT01037543</nct_id>
  </id_info>
  <brief_title>Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and PK of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Japanese and Caucasian Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design

        -  Randomized, double-blind, placebo-controlled, escalating single-dose design.

        -  Six ascending dose cohorts

        -  In each cohorts, subjects will be randomized to receive a single dose of HM10460A,
           placebo (negative control), or NeulastaÂ® (positive control).

        -  Primary Objective

        -  to assess the safety and tolerability of single escalating subcutaneous doses of
           HM10460A in healthy adult Japanese and Caucasian subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives:

        -  to assess the pharmacokinetics (PK) of a single subcutaneous dose of HM10460A.

        -  to compare the PK of HM10460A in Japanese and Caucasian subjects.

        -  to assess the relationship between the serum concentration of HM10460A and absolute
           neutrophil count (ANC).

        -  to assess the relationship between the serum concentration of HM10460A and CD34+ cell
           counts in the blood.

        -  To assess the immunogenicity potential of HM10460A by measuring binding antibodies (bAb)
           and neutralizing antibodies (nAb) to HM10460A and native G-CSF following a single
           subcutaneous dose of HM10460A.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety data, including physical examinations (to include injection site reactions and splenic evaluations), laboratory evaluations, ECGs, vital signs assessments, and adverse effects (AEs).</measure>
    <time_frame>Time points where appropriate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Samples for immunogenicity</measure>
    <time_frame>Days -1, 15, 22, and 42.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters measured from Serum and Urine samples.</measure>
    <time_frame>Serum samples: pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hrs, Days 4, 5, 6, 7, 11, 15, and 22. / Urine Samples: 0 - 6, 6 - 12, 12 - 24, 24 - 36, and 36 - 48 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of ANC and CD34+ cell counts.</measure>
    <time_frame>pre-dose, 24 and 48 hours post-dose, Days 4, 5, 6, 7, 11, 15, and 22.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.1 mcg/kg of HM10460A, placebo, or Neulasta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.3 mcg/kg HM10460A, placebo or Neulasta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mcg/kg of HM10460A, placebo, or Neulasta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mcg/kg of HM10460A, placebo, or Neulasta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mcg/kg or HM10460A, placebo, or Neulasta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>270 mcg/kg of HM10460A, placebo, or Neulasta</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A or placebo or Neulasta</intervention_name>
    <description>Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>LAPS-G-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI of 18 - 29.9 kg/m2

          -  have not used tobacco or nicotine containing products for at least 3 months prior to
             dosing

          -  be able to remain abstinent throughout the study.

        Exclusion Criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,
             or psychiatric disease.

          -  positive urine drug/alcohol testing

          -  Positive for HIV, HBsAg, HCV ab

          -  History of anaphylactic reaction to medicine or environmental exposure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanmi Clinical</last_name>
    <role>Principal Investigator</role>
    <affiliation>California</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>California</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2009</study_first_submitted>
  <study_first_submitted_qc>December 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

